
InflaRx (IFRX) Stock Forecast & Price Target
InflaRx (IFRX) Analyst Ratings
Bulls say
InflaRx is an exciting biopharmaceutical company that is utilizing innovative technologies to develop potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. With its promising product candidates, vilobelimab and izicopan, the company is targeting a wide range of inflammatory and autoimmune diseases. In particular, the potential for izicopan to effectively replace the now impaired Tavneos (avacopan) as non-steroidal standard-of-care in ANCA-associated vasculitis (AAV) gives a positive outlook on the company's future. Additionally, the company's plans for PK bridging studies in China, open-label studies in other locations, and exploring the potential of izicopan in inflammatory renal diseases demonstrate potentially strong growth opportunities. Although there are risks, including potential competition and FDA approval challenges, we remain Overweight on IFRX and have increased our price target to $8 based on our updated financial model and its promising clinical focus.
Bears say
InflaRx is facing potential clinical and competitive risks with its product candidate, Izicopan, with Phase 3 trial endpoints focused on efficacy and the need for successful trials in renal diseases. In addition, the company faces the possibility of failure in CSU and HS and subsequent need to pivot to other indications, with other potential treatments being increasingly competitive. The potential setbacks could have a significant impact on the company's future success and financial stability.
This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares